Daniel Appelbaum, MD, is both a radiologist and nuclear medicine physician. He has expertise in the full spectrum of nuclear/molecular imaging, specializing in oncologic, neurologic, cardiac and positron emission tomographic (PET and PET/CT) applications. Dr. Appelbaum and his colleagues offer a full array of both diagnostic and therapeutic nuclear exams and procedures for adults and children at the University of Chicago Medicine.
Dr. Appelbaum conducts nuclear and molecular imaging research in the basic science and clinical settings. His current work involves development of a novel brain imaging agent for multiple sclerosis, as well as a metabolic catalyst to augment tumor detection with PET imaging. Other interests include developing new strategies for using computer-aided diagnosis (CAD) in nuclear medicine, work for which he has been awarded a patent in artificial intelligence (AI). The section he leads is involved in several oncology PET/CT clinical trials that monitor how patients respond to therapy. Dr. Appelbaum chairs the University of Chicago Radioactive Drug Research Advisory Committee (RADRAC).
An active educator, Dr. Appelbaum accepts many lecture invitations on nuclear and PET imaging at hospitals and medical meetings worldwide. He is a longstanding member of the national Society of Nuclear Medicine Committee on Education. He has also published a textbook (Nuclear Medicine RadCases) designed as a comprehensive review of his field.